Clinical trials: Response To Dengue Exposure
Dengue Fever With Warning Signs
Phase 3b Trial To Evaluate Safety And Immune Response (Superiority) of a Two-Dose Butantan-DV Regimen And The Standard Single Dose In Dengue-Naive Children/Adolescents and Immune Response (Non-inferiority) in a Manufacturing Facility Change (DEN-06-IB)
This randomized, double-blind, three parallel-group, multicenter, phase 3b trial evaluates the safety and immunogenicity of Butantan-DV. The study compares two primary immunization regimens (Butantan-DV/Butantan-DV vs.
- Trial name
- DEN-06-IB (NCT07712926)
- Testing
- Butantan-DV (IB), Butantan-DV (WuXi)
- Volunteers
- 1,765 people, healthy volunteers welcome
- Sponsor
- Butantan Institute